Stockscreener 앱 받기
18.70
10.72%
1.81
시장 영업 전:
18.11
-0.59
-3.16%
전일 마감가:
$16.89
열려 있는:
$17.02
하루 거래량:
355.37K
Relative Volume:
1.43
시가총액:
$830.33M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+10.26%
1개월 성능:
-22.98%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$16.75
$19.13
1주일 범위
$16.40
$19.13
52주 변동 폭
$15.86
$28.99
Septerna Inc Stock (SEPN) Company Profile
SEPN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SEPN
Septerna Inc
|
18.70 | 830.33M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Septerna Inc Stock (SEPN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-19 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-11-19 | 개시 | JP Morgan | Overweight |
| 2024-11-19 | 개시 | TD Cowen | Buy |
| 2024-11-19 | 개시 | Wells Fargo | Overweight |
Septerna Inc 주식(SEPN)의 최신 뉴스
Septerna to Introduce Groundbreaking GPCR Drug Discovery Innovations - Defense World
Septerna (NASDAQ:SEPN) Sets New 52-Week Low – Here’s What Happened - Defense World
Septerna (NASDAQ:SEPN) Sets New 12-Month LowTime to Sell? - MarketBeat
Septerna (NASDAQ:SEPN) Trading Down 8.5%Here's Why - MarketBeat
Septerna (NASDAQ: SEPN) Appoints Gil Labrucherie as Chief Financial Officer - Defense World
Third Rock-backed Maze Therapeutics reveals profit in US IPO filing - Marketscreener.com
Septerna appoints new CFO to bolster financial strategy By Investing.com - Investing.com Australia
Septerna (NASDAQ:SEPN) Shares Gap DownTime to Sell? - MarketBeat
Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer - The Manila Times
Septerna Brings in Gil Labrucherie as Finance Chief - MarketWatch
Septerna appoints new CFO to bolster financial strategy - Investing.com
Septerna Names Biotech Veteran Gil Labrucherie as CFO, Brings $1.5B Capital Raising Success - StockTitan
Septerna (NASDAQ:SEPN) Trading 7.7% HigherShould You Buy? - MarketBeat
Septerna initiated with an Overweight at JPMorgan - MSN
Septerna (NASDAQ:SEPN) Shares Down 5%Time to Sell? - MarketBeat
Septerna (NASDAQ:SEPN) Sets New 52-Week High – Should You Buy? - Defense World
Septerna (NASDAQ:SEPN) Trading Up 8.4%Time to Buy? - MarketBeat
Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Septerna to Present GPCR Drug Discovery Pipeline at J.P. Morgan Healthcare Conference 2025 - StockTitan
Vertex Global reports ten IPOs, acquisitions worldwide in 2024 - Tech in Asia
Septerna, Inc.’s (NASDAQ:SEPN) Quiet Period Set To Expire on December 4th - Defense World
New MRGPRX2 antagonists disclosed in Septurna patent - BioWorld Online
Cantor Fitzgerald Weighs in on Septerna FY2024 Earnings - Defense World
Analysts Offer Predictions for Septerna FY2024 Earnings - MarketBeat
Septerna, Inc. Reports Q3 2024 Financials and Progress - Yahoo Finance
Septerna (NASDAQ:SEPN) Coverage Initiated at Wells Fargo & Company - Defense World
Cantor Fitzgerald Begins Coverage on Septerna (NASDAQ:SEPN) - Defense World
Septerna (NASDAQ:SEPN) Coverage Initiated at TD Cowen - Defense World
Septerna started by J.P. Morgan at overweight, GPCR platform cited - MSN
Septerna Inc. (SEPN) reports earnings - Quartz
Septerna proposes terms for upsized $175M IPO - MSN
Septerna Shares Fall 7% After Wider 3Q Loss - MarketWatch
Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights - The Manila Times
Septerna Advances Key Drug Trial, Reports $137.5M Cash Position After Successful IPO | SEPN Stock News - StockTitan
Cantor launches Septerna stock coverage, highlighting platform value and growth in GPCR drug development - Investing.com Nigeria
TD Cowen optimistic on Septerna stock as preclinical data fuels confidence - Investing.com Canada
JPMorgan bullish on Septerna stock—pipeline strategy drives optimism - Investing.com India
Septerna Poised For Biopharma Breakthrough: Analysts Cite GPCR Innovation And 2025 Milestones - AOL
Septerna started by J.P. Morgan at overweight, GPCR platform cited (NASDAQ:SEPN) - Seeking Alpha
This Apollo Global Management Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Septerna (NASDAQ:SEPN) Coverage Initiated at Cantor Fitzgerald - MarketBeat
Septerna (NASDAQ:SEPN) Now Covered by TD Cowen - MarketBeat
Septerna (NASDAQ:SEPN) Earns Overweight Rating from Analysts at JPMorgan Chase & Co. - MarketBeat
Septerna (NASDAQ:SEPN) Earns Overweight Rating from Analysts at Wells Fargo & Company - MarketBeat
JPMorgan bullish on Septerna stock—pipeline strategy drives optimism By Investing.com - Investing.com Canada
RA Capital Management's Strategic Investment in Septerna Inc - GuruFocus.com
Buffett Still Building This Stake, Plus Huge Insider Buy in Biotech IPO - 24/7 Wall St.
Wednesday's Insider Activity: Top Buys and Sells in US Stocks By Investing.com - Investing.com Australia
Nasdaq debutante Septerna swells its IPO to $331m - pharmaphorum
Septerna (NASDAQ:SEPN) Files Amendment and Restatement of Certificate of Incorporation and Bylaws - Defense World
Septerna Inc (SEPN) 재무 분석
Septerna Inc (SEPN)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):